OTCMKTS:ALPMY - Get Free Report ) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 83,900 shares, an increase of 20.2% from the April 15th total of 69,800 shares. Based on an average daily trading volume, of 1,006,700 shares, the days-to-cover ratio is currently 0.1 days.
Get Astellas Pharma alerts:
Sign Up
Astellas Pharma Stock Down 1.0 % Astellas Pharma stock opened at $9.62 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.71 and a current ratio of 0.91. Astellas Pharma has a one year low of $9.15 and a one year high of $16.91. The company has a 50-day simple moving average of $10.29 and a 200-day simple moving average of $11.21. The firm has a market capitalization of $17.41 billion, a P/E ratio of 137.43, a P/E/G ratio of 1.69 and a beta of 0.37.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report ) last posted its earnings results on Thursday, April 25th. The company reported $0.11 EPS for the quarter. The firm had revenue of $2.79 billion during the quarter. Astellas Pharma had a net margin of 1.20% and a return on equity of 5.85%. As a group, equities analysts expect that Astellas Pharma will post 0.44 earnings per share for the current year.
Astellas Pharma Company Profile (
Get Free Report )
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Stories This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
